ZA200803821B - Thiazolo [4, 5-C] pyridine derivatives as mGlu5 receptor antagonists - Google Patents

Thiazolo [4, 5-C] pyridine derivatives as mGlu5 receptor antagonists

Info

Publication number: ZA200803821B
Authority: ZA; South Africa
Prior art keywords: thiazolo; receptor antagonists; pyridine derivatives; mglu5 receptor; mglu5
Prior art date: 2005-11-08

Application number

ZA200803821A

Other languages

English (en)

Inventor

Jaeschke Georg

Richard H P Porter

Vieira Eric

Kolczewski Sabine

Schnider Patrick

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-08

Filing date

2008-05-05

Publication date

2009-03-25

2008-05-05 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2009-03-25 Publication of ZA200803821B publication Critical patent/ZA200803821B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Psychology (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

ZA200803821A 2005-11-08 2008-05-05 Thiazolo [4, 5-C] pyridine derivatives as mGlu5 receptor antagonists ZA200803821B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP05110461		2005-11-08

Publications (1)

Publication Number	Publication Date
ZA200803821B true ZA200803821B (en)	2009-03-25

Family

ID=37897285

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200803821A ZA200803821B (en)	2005-11-08	2008-05-05	Thiazolo [4, 5-C] pyridine derivatives as mGlu5 receptor antagonists

Country Status (16)

Country	Link
US (1)	US7659401B2 (fr)
EP (1)	EP1948667B1 (fr)
JP (1)	JP5015166B2 (fr)
KR (1)	KR101020431B1 (fr)
CN (1)	CN101291939B (fr)
AR (1)	AR058179A1 (fr)
AT (1)	ATE553108T1 (fr)
AU (1)	AU2006311084A1 (fr)
BR (1)	BRPI0618636A2 (fr)
CA (1)	CA2628936A1 (fr)
ES (1)	ES2382162T3 (fr)
IL (1)	IL190989A0 (fr)
RU (1)	RU2425834C2 (fr)
TW (1)	TWI323261B (fr)
WO (1)	WO2007054436A2 (fr)
ZA (1)	ZA200803821B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2696016A1 (fr) *	2007-07-13	2009-01-22	Addex Pharma S.A.	Nouveaux derives heteroaromatiques et leur utilisation en tant que modulateurs allosteriques positifs des recepteurs metabotropiques du glutamate
GB0800411D0 (en) *	2008-01-10	2008-02-20	Glaxo Group Ltd	Novel compounds
EP2513118B1 (fr) *	2009-12-18	2013-09-18	Janssen Pharmaceutica, N.V.	Thiazoles bicycliques en tant que modulateurs allostériques de récepteurs mGluR5
AU2010332811B2 (en) *	2009-12-18	2014-07-24	Janssen Pharmaceutica Nv	Bicyclic thiazoles as allosteric modulators of mGluR5 receptors
CA3015345A1 (fr)	2016-02-23	2017-08-31	Indiana University Research & Technology Corporation	Polytherapies utilisees dans le traitement de l'amyotrophie spinale
KR102224677B1 (ko)	2018-08-23	2021-03-08	가천대학교 산학협력단	티아졸로 피페라진 유도체 및 이를 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0321115B1 (fr)	1987-12-14	1991-08-14	Sawai Pharmaceutical Co., Ltd.	Carboxamides contenant un noyau tétrazole et un noyau thiazole et leur utilisation
JP2695037B2 (ja) *	1990-11-07	1997-12-24	富士通株式会社	エラーパルス延伸回路
US6107300A (en) *	1996-03-27	2000-08-22	Dupont Pharmaceuticals	Arylamino fused pyrimidines
WO1998005651A1 (fr)	1996-08-01	1998-02-12	Warner-Lambert Company	Nouveaux antagonistes de recepteurs du glutamate sous forme de quinoxalinediones fusionnees avec cycloalkyle
WO1999022298A1 (fr) *	1997-10-29	1999-05-06	Continental Teves Ag & Co. Ohg	Procede et dispositif pour controler une procedure de surveillance d'erreurs d'un circuit
US6110929A (en) *	1998-07-28	2000-08-29	3M Innovative Properties Company	Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
KR100875222B1 (ko)	1999-08-19	2008-12-19	아스트라제네카 아베	헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도
US6660753B2 (en) *	1999-08-19	2003-12-09	Nps Pharmaceuticals, Inc.	Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2002044189A1 (fr)	2000-11-30	2002-06-06	Canon Kabushiki Kaisha	Element luminescent et afficheur
JP4159361B2 (ja) *	2001-02-20	2008-10-01	中外製薬株式会社	マロニル−ＣｏＡ脱炭酸酵素阻害剤を用いた代謝性疾患の治療法
IL157491A0 (en)	2001-02-21	2004-03-28	Nps Pharmeceuticals Inc	Heteropolycyclic compounds and pharmaceutical compositions containing the same
WO2002078745A2 (fr)	2001-04-02	2002-10-10	Brown University Research Foundation	Compositions et utilisations d'antagonistes de mglur5
US6529046B1 (en) *	2001-12-12	2003-03-04	Etron Technology, Inc.	Minimum pulse width detection and regeneration circuit
JP2006512313A (ja) *	2002-10-31	2006-04-13	アムジェンインコーポレイテッド	抗炎症剤
ITMI20030151A1 (it) *	2003-01-30	2004-07-31	Recordati Ind Chimica E Farma Ceutica S P A	Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
WO2006008545A2 (fr)	2004-07-22	2006-01-26	Astex Therapeutics Limited	Composes pharmaceutiques
JP2008534664A (ja) *	2005-04-06	2008-08-28	アストラゼネカアクチボラグ	置換複素環およびｃｈｋ１、ｐｄｋ１及びｐａｋ阻害剤としてのそれらの使用

2006
- 2006-10-26 CN CN2006800386693A patent/CN101291939B/zh not_active Expired - Fee Related
- 2006-10-26 EP EP06807563A patent/EP1948667B1/fr not_active Not-in-force
- 2006-10-26 JP JP2008539390A patent/JP5015166B2/ja not_active Expired - Fee Related
- 2006-10-26 AU AU2006311084A patent/AU2006311084A1/en not_active Abandoned
- 2006-10-26 CA CA002628936A patent/CA2628936A1/fr not_active Abandoned
- 2006-10-26 BR BRPI0618636-0A patent/BRPI0618636A2/pt not_active IP Right Cessation
- 2006-10-26 KR KR1020087013474A patent/KR101020431B1/ko not_active Expired - Fee Related
- 2006-10-26 RU RU2008115034/04A patent/RU2425834C2/ru not_active IP Right Cessation
- 2006-10-26 AT AT06807563T patent/ATE553108T1/de active
- 2006-10-26 WO PCT/EP2006/067794 patent/WO2007054436A2/fr not_active Ceased
- 2006-10-26 ES ES06807563T patent/ES2382162T3/es active Active
- 2006-10-31 US US11/590,087 patent/US7659401B2/en not_active Expired - Fee Related
- 2006-11-06 AR ARP060104855A patent/AR058179A1/es not_active Application Discontinuation
- 2006-11-06 TW TW095140997A patent/TWI323261B/zh not_active IP Right Cessation
2008
- 2008-04-17 IL IL190989A patent/IL190989A0/en unknown
- 2008-05-05 ZA ZA200803821A patent/ZA200803821B/xx unknown

Also Published As

Publication number	Publication date
TW200736264A (en)	2007-10-01
AR058179A1 (es)	2008-01-23
US7659401B2 (en)	2010-02-09
AU2006311084A1 (en)	2007-05-18
RU2008115034A (ru)	2009-12-20
RU2425834C2 (ru)	2011-08-10
CN101291939B (zh)	2013-02-13
CA2628936A1 (fr)	2007-05-18
US20070105891A1 (en)	2007-05-10
WO2007054436A3 (fr)	2007-06-28
EP1948667A2 (fr)	2008-07-30
ES2382162T3 (es)	2012-06-05
KR20080069229A (ko)	2008-07-25
CN101291939A (zh)	2008-10-22
BRPI0618636A2 (pt)	2011-09-06
IL190989A0 (en)	2008-12-29
TWI323261B (en)	2010-04-11
JP5015166B2 (ja)	2012-08-29
KR101020431B1 (ko)	2011-03-08
EP1948667B1 (fr)	2012-04-11
WO2007054436A2 (fr)	2007-05-18
ATE553108T1 (de)	2012-04-15
JP2009514923A (ja)	2009-04-09

Publication	Publication Date	Title
ZA200800353B (en)	2008-12-31	Pyrazine derivatives useful as adenosine receptor antagonists
IL185326A0 (en)	2008-02-09	PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS
ZA201202026B (en)	2012-11-28	PYROLO[2,3-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
BRPI0822237A2 (pt)	2015-06-30	Compostos de imidazo [1,2-a] piridina
ZA200805354B (en)	2009-10-28	Aryl-isoxazol-4-yl-imidazo[1,5-A]pyridine derivatives
ZA200802588B (en)	2009-09-30	Imidazopyridine derivatives as A2B adenosine receptor antagonists
ZA200800320B (en)	2009-02-25	Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
IL178396A0 (en)	2007-02-11	Condensed pyridine derivatives useful as a28 adenosine receptor antagonists
AP2006003786A0 (en)	2006-10-31	Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligands
IL185912A0 (en)	2008-01-06	Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
ZA200902187B (en)	2009-11-25	8-Ethinylxanthine derivatives as selective A2A receptor antagonists
ZA200705085B (en)	2008-08-27	2,3,4,9-Tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists
PL2124944T3 (pl)	2012-08-31	Pochodne pirazolo[3,4-b]pirydyny jako inhibitory fosfodiesterazy
IL192308A0 (en)	2009-02-11	Oxazoloisoquinoline derivatives as thrombin receptor antagonists
ZA200803821B (en)	2009-03-25	Thiazolo [4, 5-C] pyridine derivatives as mGlu5 receptor antagonists
PL1636206T3 (pl)	2008-04-30	Pochodne imidazolu jako antagoniści receptorów glutaminianu
IL178622A0 (en)	2007-02-11	Piperazinylpiperidine derivatives as chemokine receptor antagonists
ZA200903496B (en)	2010-03-31	Spiro-piperidine derivatives as via receptor antagonists
PL1912976T3 (pl)	2009-04-30	Pochodne indol-3-ilokarbonylopiperydynobenzoimidazolu jako antagoniści receptora V1a
HUP0501169A3 (en)	2008-03-28	New phenantridine derivatives as selective bradykinin b1 receptor antagonists
IL188924A0 (en)	2008-08-07	Imidazopyridine derivatives as cannabinoid receptor ligands
ZA200800354B (en)	2008-12-31	Imidazopyridine derivatives as cannabinoid receptor ligands
HK1132499A (en)	2010-02-26	8-ethinylxanthine derivatives as selective a2a receptor antagonists
ZA200705987B (en)	2009-05-27	Substituted pyridine derivatives
HK1111156A (en)	2008-08-01	Pyrazine derivatives useful as adenosine receptor antagonists